# A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

> **NCT04688021** · PHASE2 · UNKNOWN · sponsor: **Yi Luo** · enrollment: 46 (estimated)

## Conditions studied

- Leukemia
- Graft-versus-host-disease

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Busulfan
- **DRUG:** Cyclophosphamide
- **DRUG:** Me-CCNU
- **DRUG:** Rabbit antithymocyte globulin
- **DRUG:** Tocilizumab
- **PROCEDURE:** Allogeneic HSCT
- **DRUG:** Cyclosporin A
- **DRUG:** Mycophenolate Mofetil
- **DRUG:** MTX

## Key facts

- **NCT ID:** NCT04688021
- **Lead sponsor:** Yi Luo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-03
- **Primary completion:** 2024-12-03
- **Final completion:** 2024-12-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04688021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04688021, "A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04688021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*